Bonus BioGroup
Viable Tissue-regenerating Bone Grafts
Company Overview
Snapshot
Founded in October 1981 by Shai Meretzki and Prof. Avinoam Kadouri, Bonus BioGroup operates with 11–50 employees. The company has raised $25.6 million across five funding rounds. Bonus BioGroup became publicly listed on the TASE in February 2012.
Business overview
Bonus BioGroup is a product-focused biotechnology company specializing in tissue-regenerating, viable bone grafts. The company develops cell therapy and tissue-engineering products based on autologous bone implants for efficient bone transplantation and replacement of bone lesions. Its core technology, BonoFill, creates high-density 3D bone grafts from a patient's own cells, grown ex vivo in a bioreactor system. This personalized approach aims to prevent immune reactions and graft rejection, serving the healthcare and life sciences sectors, particularly in orthopedics and regenerative medicine.
Strategic signal
In September 2024, Bonus BioGroup received patent approval from the European and English patent offices, indicating significant progress in securing intellectual property for its biotechnology innovations. This development suggests a strengthening of the company's market position and potential for broader commercialization of its tissue-engineering products, signaling increased investor confidence in its proprietary technology.
Log in to access full profile ›Company Intelligence Q&A
- What is Bonus BioGroup's primary focus?
- Bonus BioGroup is primarily focused on developing tissue-regenerating, viable bone grafts using proprietary cell therapy and tissue-engineering technologies.
- When did Bonus BioGroup become a public company?
- Bonus BioGroup became publicly listed on the TASE in February 2012.
- What is BonoFill?
- BonoFill is Bonus BioGroup's method for growing high-density 3D bone grafts based on multicell 3D cultures, derived from a patient's own cells for personalized bone replacement.
- What significant intellectual property milestone did Bonus BioGroup achieve in September 2024?
- In September 2024, Bonus BioGroup received patent approval from the European and English patent offices for its technology.
- What was a key development regarding MesenCure in February 2025?
- In February 2025, Bonus BioGroup announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) Application for a MesenCure™ Phase III Clinical Study in Respiratory Distress.